Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhitan Anshen Granules is a Traditional Chinese Medicine (TCM) hospital preparation developed by the Hubei Provincial Hospital of Integrated Chinese and Western Medicine. It is specifically formulated for the treatment of cerebral infarction (ischemic stroke), particularly during the recovery and convalescent phases. The preparation is designed to address neurological deficits and associated psychological symptoms by tonifying Qi, activating blood circulation to resolve stasis, and tranquilizing the mind (Anshen). Clinical use focuses on improving symptoms such as hemiplegia, speech impairment, insomnia, and anxiety in post-stroke patients. As a hospital preparation in China, it is approved for use within the developing institution's clinical network and is often used as part of an integrated approach combining Western medicine and traditional therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhitan Anshen Granules.